De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia
Berthony Deslouches1, Ivan A Gonzalez, Dilhari DeAlmeida
1Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Objectives:
We describe the antimicrobial activity against Pseudomonas aeruginosa of the de novo-derived antimicrobial peptide WLBU2 in an animal model of infection.
Methods:
For this study, an intravenous (iv) model of P. aeruginosa infection was established. The minimum lethal murine dose of P. aeruginosa strain PA01 was determined to be 3 x 10(7) cfu when bacteria were administered iv. Increasing concentrations of WLBU2 were instilled either prior to or following PA01 septic exposure.
Results:
For the mice given peptide post-bacterial infection, in the 1 mg/kg group, nine of nine animals died because of Pseudomonas sepsis; in the 3 mg/kg group, only one of nine succumbed to infection and in the 4 mg/kg group, all mice were protected (P < 0.0001). Similar results were obtained when WLBU2 was given 1 h prior to Pseudomonas infection.
Conclusions:
Although the therapeutic window in this model is narrow, the results nonetheless provide encouraging evidence for WLBU2 as a potential prophylactic or treatment of bacterial infection.
Insights
The antimicrobial peptide WLBU2 shows promise in treating Pseudomonas aeruginosa infections. In an animal model, WLBU2 effectively protected mice against lethal bacterial sepsis, indicating its potential as a therapeutic agent.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa is a significant opportunistic pathogen causing severe infections.
- Antimicrobial peptides represent a promising class of therapeutics against drug-resistant bacteria.
- WLBU2 is a novel de novo-designed antimicrobial peptide.
Purpose of the Study:
- To evaluate the efficacy of WLBU2 against Pseudomonas aeruginosa in a murine model of infection.
- To determine the protective effects of WLBU2 when administered prophylactically or therapeutically.
Main Methods:
- An intravenous model of P. aeruginosa infection was established in mice.
- The minimum lethal dose of P. aeruginosa strain PA01 was determined.
- Increasing concentrations of WLBU2 were administered before or after bacterial challenge.
Main Results:
- WLBU2 demonstrated dose-dependent protection against P. aeruginosa sepsis.
- Complete protection was observed at a dose of 4 mg/kg when administered post-infection (P < 0.0001).
- Similar protective effects were noted when WLBU2 was given prophylactically.
Conclusions:
- WLBU2 exhibits significant antimicrobial activity against P. aeruginosa in a preclinical model.
- Despite a narrow therapeutic window, WLBU2 shows potential as a prophylactic or treatment for bacterial infections.
- Further investigation into WLBU2 is warranted for its clinical development.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:23Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:28Gene Regulation in Microbial Communities: Quorum Sensing